CANbridge Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

$224.1M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • CANbridge Pharmaceuticals's estimated annual revenue is currently $15.3M per year.(i)
  • CANbridge Pharmaceuticals's estimated revenue per employee is $201,000
  • CANbridge Pharmaceuticals's total funding is $224.1M.

Employee Data

  • CANbridge Pharmaceuticals has 76 Employees.(i)
  • CANbridge Pharmaceuticals grew their employee count by 7% last year.

CANbridge Pharmaceuticals's People

NameTitleEmail/Phone
1
Founder, chairman and CEOReveal Email/Phone
2
Chief Commercial Officer (CCO)Reveal Email/Phone
3
Head CMC and Process DevelopmentReveal Email/Phone
4
VP Regulatory Affairs JobsReveal Email/Phone
5
Head Information TechnologyReveal Email/Phone
6
Director Investor RelationsReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
8
Chief Commercial OfficerReveal Email/Phone
9
Senior Director, CMCReveal Email/Phone
10
VP/Head Global ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is CANbridge Pharmaceuticals?

CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region. CANbridge has been recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, it has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnology's NERLYNX® (neratinib), in greater China, as well as rights to other novel candidates.

keywords:N/A

$224.1M

Total Funding

76

Number of Employees

$15.3M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CANbridge Pharmaceuticals News

2022-03-22 - CANbridge Pharmaceuticals CAN108 New Drug Application ...

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food...

2022-03-22 - First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment ...

CANbridge Pharmaceuticals Inc. (“CANbridge,” stock code 1228.HK) is a China-based global biopharmaceutical company committed to the research,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.8M760%N/A
#2
$24.7M76-3%N/A
#3
$11M76N/AN/A
#4
$13.7M769%N/A
#5
$13.7M7623%N/A